博瑞生物医药（苏州）股份有限公司第四届监事会第八次会议决议公告

Core Viewpoint - The company is adjusting its plan for a specific issuance of A-shares to certain investors, including changes in pricing, issuance quantity, and lock-up periods, in response to recent equity distributions and regulatory requirements [2][21][35]. Meeting Details - The fourth supervisory board meeting was held on July 18, 2025, with all five supervisors present, and the meeting complied with legal and regulatory requirements [1]. Issuance Plan Adjustments - The pricing benchmark date for the issuance is set as the date of the board meeting announcement, with the adjusted initial issuance price being 22.36 yuan per share, down from 22.56 yuan due to equity distributions [3][5][41]. - The maximum number of shares to be issued is adjusted to 22,361,359 shares, which does not exceed 30% of the company's total share capital prior to the issuance [7][37]. Lock-up Period Changes - The lock-up period for shares acquired in this issuance has been extended from 36 months to 48 months [10][43]. Financial Impact Analysis - The company has conducted a thorough analysis of the financial impact of the issuance on key metrics such as earnings per share, assuming various scenarios for net profit growth [21][23]. - The projected net profit for 2024 is 189.17 million yuan, with scenarios considering a 10% increase, no change, or a 10% decrease for 2025 [21]. Use of Proceeds - The funds raised from this issuance, not exceeding 500 million yuan, will be used to supplement working capital and repay bank loans, which is expected to enhance the company's financial structure and reduce financial risks [37][45]. Related Party Transactions - The issuance involves a related party transaction with Yuan Jiandong, a major shareholder and actual controller of the company, who will fully subscribe to the shares issued [35][39]. Compliance and Governance - The issuance plan has been reviewed and approved by the board and supervisory committee, ensuring compliance with relevant laws and regulations [49].